Home/Pipeline/AP-001

AP-001

Pancreatic Cancer

Pre-clinicalActive

Key Facts

Indication

Pancreatic Cancer

Phase

Pre-clinical

Status

Active

Company

Avenzoar Pharmaceuticals

About Avenzoar Pharmaceuticals

Avenzoar Pharmaceuticals is a private, pre-clinical stage biotech focused on developing novel small molecule drugs against cancer metastasis and therapy resistance, with a lead program, AP-001, targeting pancreatic cancer. The company differentiates itself through a proprietary AI platform that analyzes multi-modal tumor data to predict outcomes and guide drug development. With plans to engage the FDA in early 2026 and initiate clinical trials in 2027, Avenzoar aims to address significant unmet needs in oncology, though it remains pre-revenue and faces the typical high-risk path of drug development.

View full company profile

Therapeutic Areas

Oncology

Other Pancreatic Cancer Drugs

Drug	Company	Phase	Status
Ampligen® (rintatolimod)	AIM ImmunoTech	Early Access Program	Active - Approved in the Netherlands at Erasmus MC
HBM9027	Harbour BioMed	Phase 1	Active (Global)
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
AHPBA IRE Registry	AngioDynamics	Post-Market Registry	Active
SIMBs + Immunotherapy	Advanced Microbubbles	Pre-clinical	Validated in preclinical studies
CLS-014	CLS Therapeutics	Pre-clinical	Lead candidate
SOMA Platform	Coherence Neuro	Pre-clinical	Pipeline expansion launched in 2024
NP-G2-044	Novita Pharmaceuticals	Phase 2a	Orphan Drug Designated (Jan 2026)
Pritumumab (PTB)	Nascent Biotech	Phase II (Planned)	Exploratory
Pancreatic Cancer Test	Mosaique Diagnostic	Development	Active
Iontophoretic System	Continuity Biosciences	Pre-clinical	Active
Lixumistat (IM156)	ImmunoMet Therapeutics	Phase 1b	Active